Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer

被引:20
作者
Choi, J
Kong, K
Mozaffar, T
Holcombe, RF
机构
[1] Univ Calif Irvine, Irvine Med Ctr, Div Hematol Oncol, Orange, CA 92868 USA
[2] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92868 USA
[3] Univ Calif Irvine, Dept Neurol, Orange, CA 92868 USA
关键词
adjuvant chemotherapy; chemotherapy toxicity; colon cancer; oxaliplatin; sensory neuropathy;
D O I
10.1097/01.cad.0000185185.64980.70
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Oxaliplatin-containing chemotherapy regimens are utilized commonly for metastatic colorectal cancer and increasingly in the adjuvant setting following surgical resection. The dose-limiting toxicity is neurotoxicity. Acute neurotoxicity is cold induced and transient. Chronic neurotoxicity usually has a predictable clinical course. It is manifested by paresthesias and dysesthesias of gradually prolonged duration that occur between treatment cycles, and increase in intensity and duration with the cumulative dose. We report here a case of a patient who developed significant grade 3 chronic neuropathy following completion of 6 months of adjuvant oxaliplatin-containing chemotherapy for stage III colon cancer. The neurotoxicity was not preceded by any transient symptoms characteristic of chronic oxaliplatin neuropathy and its onset was unpredictable. Delayed neurotoxicity is a complication which must be considered for patients receiving adjuvant therapy and attempts to utilize the minimum effective cumulative dose of oxaliplatin are warranted.
引用
收藏
页码:103 / 105
页数:3
相关论文
共 18 条
[1]
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]
BRIENZA S, 1995, P AN M AM SOC CLIN, V14, P209
[3]
Oxaliplatin-associated neuropathy: A review [J].
Cersosimo, RJ .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (01) :128-135
[4]
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures [J].
Gamelin, E ;
Gamelin, L ;
Bossi, L ;
Quasthoff, S .
SEMINARS IN ONCOLOGY, 2002, 29 (05) :21-33
[5]
GAMELIN E, 2002, P AN M AM SOC CLIN, V21, pA157
[6]
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].
Goldberg, RM ;
Sargent, DJ ;
Morton, RF ;
Fuchs, CS ;
Ramanathan, RK ;
Williamson, SK ;
Findlay, BP ;
Pitot, HC ;
Alberts, SR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30
[7]
Oxaliplatin-safety profile: Neurotoxicity [J].
Grothey, A .
SEMINARS IN ONCOLOGY, 2003, 30 (04) :5-13
[8]
GROTHEY A, 2002, P AN M AM SOC CLIN, V21, pA219
[9]
Grothey Axel, 2005, Clin Colorectal Cancer, V5 Suppl 1, pS38, DOI 10.3816/CCC.2005.s.006
[10]
Oxaliplatin-induced neurotoxicity and the development of neuropathy [J].
Krishnan, AV ;
Goldstein, D ;
Friedlander, M ;
Kiernan, MC .
MUSCLE & NERVE, 2005, 32 (01) :51-60